SPG11 anticorps (C-Term)

N° du produit ABIN6991060

Cet anticorps Lapin Polyclonal détecte spécifiquement SPG11 dans ELISA, WB et IHC (p). Il présente une réactivité envers Humain, Souris et Rat.

Aperçu rapide pour SPG11 anticorps (C-Term) (ABIN6991060)

Antigène: SPG11 (Spastic Paraplegia 11 (Autosomal Recessive) (SPG11))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SPG11 est non-conjugé

Application: ELISA, Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-SPG11 anticorps

Épitope: AA 2360-2410, C-Term

Purification: SPG11 Antibody is affinity chromatography purified via peptide column.

Immunogène: SPG11 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human SPG11. The immunogen is located within amino acids 2360 - 2410 of SPG11.

Isotype: IgG

Information d'application

Indications d'application: SPG11 antibody can be used for detection of SPG11 by Western blot at 0.5 - 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μ,g/mL.

Antibody validated: Western Blot in mouse samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: SPG11 Antibody is supplied in PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,4 °C

Stockage commentaire: SPG11 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur SPG11

Antigène: SPG11 (Spastic Paraplegia 11 (Autosomal Recessive) (SPG11))

Autre désignation: SPG11

Sujet: SPG11 Antibody: Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders.  Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a relatively frequent form of complicated hereditary spastic paraplegia (cHSP) in which mental retardation and muscle stiffness at onset are followed by slowly progressive paraparesis and cognitive deterioration. Mutations of the SPG11 gene encoding the spatacsin protein have been identified as a major cause of HSP-TCC. Spatacsin is a potential transmembrane protein that is phosphorylated upon DNA damage. It is expressed in all structures of the brain, with a high expression in the cerebellum. SPG11 mutations may occur more frequently in familial than sporadic forms of cHSP without TCC. Kjellin syndrome is found to be associated with mutations in not only the SPG15 gene but also SPG11 gene.  Recent studies show Parkinsonism may initiate SPG11-linked HSP TCC and that SPG11 may cause juvenile Parkinsonism.

ID gène: 80208

UniProt: Q96JI7